vs
Side-by-side financial comparison of Bandwidth Inc. (BAND) and Protagonist Therapeutics, Inc (PTGX). Click either name above to swap in a different company.
Bandwidth Inc. is the larger business by last-quarter revenue ($208.8M vs $170.6M, roughly 1.2× Protagonist Therapeutics, Inc). Protagonist Therapeutics, Inc runs the higher net margin — 77.2% vs 1.9%, a 75.2% gap on every dollar of revenue. On growth, Protagonist Therapeutics, Inc posted the faster year-over-year revenue change (184.4% vs 20.1%). Protagonist Therapeutics, Inc produced more free cash flow last quarter ($182.8M vs $-1.0M).
Bandwidth Inc. is a communications platform as a service company. It sells software application programming interfaces for voice, text messaging and emergency services, using its own global IP voice network.
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel peptide-based targeted therapies for unmet medical needs, primarily covering gastrointestinal disorders, inflammatory diseases and rare disease indications. Its lead product candidates target inflammatory bowel disease and other chronic immune-related conditions, with operations spanning global R&D and partnership collaborations.
BAND vs PTGX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $208.8M | $170.6M |
| Net Profit | $4.0M | $131.7M |
| Gross Margin | 37.3% | — |
| Operating Margin | 60.5% | 74.3% |
| Net Margin | 1.9% | 77.2% |
| Revenue YoY | 20.1% | 184.4% |
| Net Profit YoY | 200.0% | 381.7% |
| EPS (diluted) | $-0.08 | $2.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $208.8M | — | ||
| Q4 25 | $207.7M | — | ||
| Q3 25 | $191.9M | — | ||
| Q2 25 | $180.0M | — | ||
| Q1 25 | $174.2M | — | ||
| Q4 24 | $210.0M | $170.6M | ||
| Q3 24 | $193.9M | — | ||
| Q2 24 | $173.6M | — |
| Q1 26 | $4.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $-1.2M | — | ||
| Q2 25 | $-4.9M | — | ||
| Q1 25 | $-3.7M | — | ||
| Q4 24 | — | $131.7M | ||
| Q3 24 | $413.0K | — | ||
| Q2 24 | $4.1M | — |
| Q1 26 | 37.3% | — | ||
| Q4 25 | 37.6% | — | ||
| Q3 25 | 38.5% | — | ||
| Q2 25 | 39.8% | — | ||
| Q1 25 | 41.0% | — | ||
| Q4 24 | 36.4% | — | ||
| Q3 24 | 37.7% | — | ||
| Q2 24 | 37.3% | — |
| Q1 26 | 60.5% | — | ||
| Q4 25 | -1.9% | — | ||
| Q3 25 | -1.0% | — | ||
| Q2 25 | -2.1% | — | ||
| Q1 25 | -2.7% | — | ||
| Q4 24 | -1.3% | 74.3% | ||
| Q3 24 | -0.5% | — | ||
| Q2 24 | -3.5% | — |
| Q1 26 | 1.9% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | -0.6% | — | ||
| Q2 25 | -2.7% | — | ||
| Q1 25 | -2.1% | — | ||
| Q4 24 | — | 77.2% | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 2.3% | — |
| Q1 26 | $-0.08 | — | ||
| Q4 25 | $-0.10 | — | ||
| Q3 25 | $-0.04 | — | ||
| Q2 25 | $-0.16 | — | ||
| Q1 25 | $-0.13 | — | ||
| Q4 24 | $0.27 | $2.01 | ||
| Q3 24 | $0.01 | — | ||
| Q2 24 | $-0.17 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $47.3M | $418.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $405.7M | $675.3M |
| Total Assets | $984.2M | $744.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $47.3M | — | ||
| Q4 25 | $111.3M | — | ||
| Q3 25 | $80.4M | — | ||
| Q2 25 | $68.1M | — | ||
| Q1 25 | $41.7M | — | ||
| Q4 24 | $83.8M | $418.9M | ||
| Q3 24 | $79.9M | — | ||
| Q2 24 | $76.4M | — |
| Q1 26 | $405.7M | — | ||
| Q4 25 | $400.0M | — | ||
| Q3 25 | $392.7M | — | ||
| Q2 25 | $384.5M | — | ||
| Q1 25 | $345.4M | — | ||
| Q4 24 | $312.5M | $675.3M | ||
| Q3 24 | $336.6M | — | ||
| Q2 24 | $307.4M | — |
| Q1 26 | $984.2M | — | ||
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $964.4M | — | ||
| Q4 24 | $989.2M | $744.7M | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $1.0B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $184.2M |
| Free Cash FlowOCF − Capex | $-1.0M | $182.8M |
| FCF MarginFCF / Revenue | -0.5% | 107.1% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | — | 1.40× |
| TTM Free Cash FlowTrailing 4 quarters | — | $101.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $38.6M | — | ||
| Q3 25 | $22.2M | — | ||
| Q2 25 | $31.7M | — | ||
| Q1 25 | $-3.1M | — | ||
| Q4 24 | $36.5M | $184.2M | ||
| Q3 24 | $20.5M | — | ||
| Q2 24 | $24.4M | — |
| Q1 26 | $-1.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $182.8M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | -0.5% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 107.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.40× | ||
| Q3 24 | 49.55× | — | ||
| Q2 24 | 6.03× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
